Product Description
CDK2/CyclinA2 is a serine/threonine kinase complex composed of the catalytic subunit CDK2 (cyclin-dependent kinase 2) and the regulatory subunit Cyclin A2, which plays a pivotal role in cell cycle progression, specifically driving the transition from G1 phase to S phase and facilitating DNA replication initiation. The CDK2/CyclinA2 complex phosphorylates key substrates such as retinoblastoma protein (RB) and components of the replication machinery, ensuring proper S-phase entry and progression. Beyond its essential physiological functions in cell division, dysregulation of CDK2/CyclinA2 signaling—including overexpression, gene amplification, and aberrant activation—is frequently observed in a wide range of human cancers, such as breast, ovarian, colorectal, and hematologic malignancies, contributing to uncontrolled proliferation, genomic instability, and therapeutic resistance. These features have established CDK2/CyclinA2 as a highly validated target for cancer therapy and drug discovery.
Screeningbio’s CDK2/CyclinA2 Kinase Assay Kit provides a robust, sensitive, and high-throughput platform for quantifying CDK2/CyclinA2 kinase activity and evaluating the potency of tyrosine kinase inhibitors (TKIs).
This kit utilizes the ADP-Glo Kinase Assay platform, a luminescent technology that measures the amount of ADP produced during the kinase reaction.
The assay is performed in two distinct steps:
Kinase Reaction: CDK2/CyclinA2 catalyzes the transfer of a phosphate group from ATP to a specific substrate, resulting in the production of phosphorylated substrate and ADP.
ADP-Glo™ Reagent Addition: After the kinase reaction, the ADP-Glo™ Reagent is added to terminate the reaction and deplete any remaining unreacted ATP.
Kinase Detection: The Kinase Detection Reagent is added to simultaneously convert the produced ADP back into ATP, which is then used by luciferase to generate a luminescent signal.
The light intensity produced is directly proportional to the ADP concentration and, consequently, to the enzymatic activity of the CDK2/CyclinA2 kinase.
Data